[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100564962":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":18,"locations":23,"responsibleParty":45,"collaborators":49,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":7,"maxAge":7,"enrollmentInfo":66,"targetDuration":69,"studyType":70,"phases":7,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":26,"whyStopped":7,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Chongqing Medical University","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DIAGNOSTIC_TEST","68Ga-Pentixafor PET\u002FCT","The patients had a normal diet with no special preparation before 68Ga-Pentixafor PET\u002FCT imaging. The dosage of intravenously injected 68Ga-Pentixafor was calculated based on the patient\\'s weight (1.85 MBq \\[0.05mCi\\]\u002Fkg). Local PET\u002FCT scanning of the upper abdomen was performed on a hybrid PET\u002FCT scanner at 10 minutes after the injection of the intravenous tracer, respectively.",[14],{"name":15,"affiliation":16,"role":17},"Qi fu Li, PhD","the Chongqing Primary Aldosteronism Study (CONPASS) Group","STUDY_CHAIR",[19],{"name":15,"role":20,"phone":21,"phoneExt":7,"email":22},"CONTACT","86-89011552","liqifu@yeah.net",[24],{"facility":25,"status":26,"city":27,"state":28,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"The First Affilated Hospital of Chongqing Medical University","RECRUITING","Chongqing","Chongqing Municipality","400016","China","CN",{"type":33,"coordinates":34},"Point",[35,36],106.55771,29.56026,{"lat":36,"lon":35},[39,42],{"name":40,"role":20,"phone":41,"phoneExt":7,"email":22},"Qifu Li, PhD","023-89011552",{"name":43,"role":20,"phone":41,"phoneExt":7,"email":44},"Ying Song, M.D.","shuiyunying@126.com",{"type":46,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"SPONSOR_INVESTIGATOR","Qifu Li","Primary investigator",[50,52,54,56],{"name":51,"class":6},"The First Affiliated Hospital of Zhengzhou University",{"name":53,"class":6},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School",{"name":55,"class":6},"The Third Xiangya Hospital of Central South University",{"name":57,"class":6},"The Affiliated Hospital Of Southwest Medical University","100564962","accuracy-of-68ga-pentixafor-petct-for-subtypting-diagnosis-in-patients-with-primary-aldosteronism-concurrent-with-autonomous-cortisol-secretion-100564962",false,"NCT06635993","Accuracy of 68Ga-Pentixafor PET\u002FCT for Subtypting Diagnosis in Patients With Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion","ABOARD","Inclusion Criteria:\n\n1. Getting the written informed consent\n2. The clear diagnosis of primary aldosteronism；\n3. Combined with autonomous cortisol secretion, cortisol after 1mg dexamethasone suppression test (DST) ≥50 nmol\u002Fl；\n4. Patients who are willing to undergo surgery；\n5. Adrenal CT or MRI scan of the adrenal glands with nodule (≥1cm).\n\nExclusion Criteria:\n\n1. PA patients who meet the by-passing AVS criteria \\[i.e., younger than 35 years old, spontaneous hypokalemia, adrenal CT indicated unilateral low-density adenoma (≥1cm), plasma aldosterone \\>300pg\u002Fml\\]；\n2. Suspicion of familial hyperaldosteronism or Liddle syndrome. \\[i.e., age \\<20 years, hypertension and hypokalemia, or with family history\\]；\n3. Suspicion of pheochromocytoma or adrenal carcinoma；\n4. Patients with actively malignant tumor；\n5. Patients who have adrenalectomy history；\n6. Long-term use of glucocorticoids；\n7. Patients who are allergic to contrast media and cannot tolerate AVS；\n8. Pregnant or lactating women; with alcohol or drug abuse and mental disorders；\n9. Congestive heart failure with New York Heart Association (NYHA) Functional Classification III or IV; History of serious cardiovascular or cerebrovascular disease (angina, myocardial infarction or stroke) in the past 3 months; Severe anemia (Hb\\<60g\u002FL); Serious liver dysfunction or chronic kidney disease aspartate aminotransferase (AST) or alanine transaminase (ALT) ≥3 times the upper limit of normal, or estimated glomerular filtration rate (eGFR) \\<30 ml\u002Fmin\u002F1.73 m2); Systemic Inflammatory Response Syndrome (SIRS); Uncontrolled diabetes (FBG≥13.3 mmol\u002FL); Obesity (BMI≥35 kg\u002Fm²); Untreated aneurysm; Other comorbidity potentially interfering with treatment；\n10. Consider patients with bilateral cortisol hypersecretion such as PBMAH or PPNAD.","ALL",{"count":67,"type":68},97,"ESTIMATED","6 Months","OBSERVATIONAL","To evaluate the accuracy of 68Ga-Pentixafor PET-CT in the classification diagnosis of primary aldosteronism concurrent with autonomous cortisol secretion patient, using AVS and\u002For postoperative remission as the reference standard for classification diagnosis.",[73],"Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion",[75,76,77,11],"primary aldosteronism","autonomous cortisol secretion","Adrenal venous sampling","2024-10-09",{"date":80,"type":81},"2024-10-10","ACTUAL",{"date":83,"type":81},"2024-08-12",{"date":85,"type":68},"2027-08-12",{"name":47,"class":6},1]